Abstract:Abstract The microtubule (MT) cytoskeleton is an effective and validated target for cancer chemotherapeutic drugs. Currently, anti-MT drug taxane, e.g. docetaxel, is the first-line chemotherapeutic agent to treat patients with locally advanced or metastatic breast cancer and is also one of the most effective chemotherapeutic agents in clinical use in six different cancers (breast, ovarian, non-small cell lung, prostate, gastric, and head and neck). Nearly half of the treated breast and ovarian cancer patients, however, do not respond to chemotherapy. Although general mechanisms of drug resistance may apply to docetaxel resistance, more specifically, the current research paradigm on docetaxel resistance focus on acquired -tubulin mutations and altered expression of β-tubulin isotypes that interfere with drug target binding. Synuclein gamma (SNCG) is a new unfavorable prognostic marker for breast cancer and a potential target for cancer treatment. At the cellular level, SNCG increases metastasis and promotes genetic instability. At the molecular level, SNCG functions like a tumor specific chaperone and regulates many pathways in growth and progression of cancer, including an interaction with mitotic checkpoint kinase BubR1. Here, we show that expression of SNCG is sufficient to induce specific resistance to docetaxel-caused mitotic arrest and apoptosis in breast cancer cells and in breast cancer xenografts. SNCG binds to spindle checkpoint kinase BubR1, interferes with its interaction with other checkpoint proteins of p55cdc20-APC and Mda2, reduces BubR1's kinase activity, and thus attenuates docetaxel-caused mitotic cell death. The working mechanism of anti-MT drugs heavily relies on the normal function of the checkpoint machinery in which BubR1 is a critical component, this inhibitory effect of SNCG on BubR1 function may lead to the inactivation of checkpoint and thus renders docetaxel resistance. To test the clinical relevance, in a pilot neoadjuvant trial, 20 women with histological proven locally advanced breast cancer were treated with 3 cycles of neoadjuvant TE regimen (docetaxel + epirubicin). SNCG-positive tumors are resistant to anticancer effect of neoadjuvant therapy as assayed by reduction in primary tumor size, an increase in apoptotic index, and a decrease in Ki67 proliferation index. These data show that SNCG renders docetaxel resistance by inhibiting BubR1 activity and is new biomarker for predicting anti-MT drug resistance. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-64.

Relationship between β-tubulin mRNA expression and sensitivity to docetaxel in malignant effusions from non small-cell lung cancer (NSCLC) and gastric cancer patients

Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer

Abstract LB-64: Synuclein Gamma Inhibits BubR1 Function and Renders Resistance to Antimicrotubule Drug

Beta-Tubulin III Mrna Expression and Docetaxel Sensitivity in Non-Small Cell Lung Cancer

Relationship Between Mrna Expression of BRCA1 and Β-Tubulin III in Malignant Effusions and Ex Vivo Chemosenstitivity to Docetaxel

Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance

Systematic profiling of Taxol resistance and sensitivity to tubulin missence mutations at molecular and cellular levels

Microtubule-Binding Natural Products for Cancer Therapy

Biological evaluation and molecular modelling study of podophyllotoxin derivatives as potent inhibitors of tubulin polymerization.

Class Ⅲ β-tubulin expression in advanced non-small cell lung cancer patients receiving tubulin-binding agents

Discovery of novel microtubule stabilizers targeting taxane binding site by applying molecular docking, molecular dynamics simulation, and anticancer activity testing

betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer.

Combination of Microtubule Associated Protein-Tau and Β-Tubulin III Predicts Chemosensitivity of Paclitaxel in Patients with Advanced Gastric Cancer.

A review of research progress of antitumor drugs based on tubulin targets

A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs.

A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells

Novel Therapeutic Potential in Targeting Microtubules by Nanoparticle Albumin-Bound Paclitaxel in Hepatocellular Carcinoma

The Relationships Between the Chemosensitivity of Human Gastric Cancer to Paclitaxel and the Expressions of Class III Β-Tubulin, MAPT, and Survivin

Anti-tumor Selectivity of a Novel Tubulin and HSP90 Dual-Targeting Inhibitor in Non-Small Cell Lung Cancer Models.

Discovery of microtubule stabilizers with novel scaffold structures based on virtual screening, biological evaluation, and molecular dynamics simulation

Tubulin degradation: Principles, agents, and applications